P A
Bluelighter
may possess too strong dissociative properties than one would rather tolerate
It is again, strictly a matter of adequate dose. I'm not aware of a documented difference in therapeutic range/side effect profile between methorphan and its active metabolite. Further, from what little I can glean from the sparse literature on the topic, dextrorphan is easily the more active of the two at the NMDA complex; it also appears to be far more selective in that manner, and as such would (theoretically) be a much better candidate for chronic use than DXM with respect to dose parsimony, crude efficiency, and, I'd be willing to wager, tolerability. Given the typically egregious prices of DXM-only OTC cough suppressants, its cost-effectiveness is very likely to be superior as well, at least when purchased in bulk.
I'd give it some thought.
Last edited: